 Shares of mental health biopharma Atai Life Sciences N.V. have fallen some two-thirds from their June 2021 IPO pricing as the biotech market continues to crater. The companys approach of identifying in many instances psychedelic compounds that have been tested in previous human trials marginally de-risks its programs. 